Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.

Burge, M R; Waters, D L; Holcombe, J H; Schade, D S

Burge, M R; Waters, D L; Holcombe, J H; Schade, D S.

Affiliation

Burge MR; Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

J Clin Endocrinol Metab ; 82(3): 920-4, 1997 Mar.

Article in En | MEDLINE | ID: mdl-9062507

Subject(s)

Diabetes Mellitus, Type 1/drug therapy; Hypoglycemic Agents/therapeutic use; Insulin, Long-Acting/therapeutic use; Insulin/analogs & derivatives; Adult; Blood Glucose/analysis; Diabetes Mellitus, Type 1/blood; Drug Combinations; Eating; Female; Humans; Hypoglycemia/chemically induced; Hypoglycemic Agents/adverse effects; Insulin/adverse effects; Insulin/blood; Insulin/therapeutic use; Insulin Lispro; Insulin, Long-Acting/adverse effects; Male; Time Factors; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Insulin, Long-Acting / Diabetes Mellitus, Type 1 / Hypoglycemic Agents / Insulin Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Female / Humans / Male Language: En Journal: J Clin Endocrinol Metab Year: 1997 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links